Co-Authors
This is a "connection" page, showing publications co-authored by Yeming Wang and Xiaohui Zou.
Connection Strength
0.290
-
Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. EBioMedicine. 2020 Dec; 62:103125.
Score: 0.229
-
Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerg Microbes Infect. 2021 Dec; 10(1):664-676.
Score: 0.061